Dosage and Administration Guidelines for Combined Therapy

The Journal of Biological Chemistry, 286(9), 6825–6838.) To view or add a comment, sign in Recent research demonstrates that gender-affirming hormone therapy can significantly alter blood protein profiles in transgender women, aligning them more closely with those of cisgender women. These changes may influence susceptibility to certain health conditions, including autoimmune diseases and heart disease. The findings highlight the importance of nuanced, long-term health monitoring and suggest that personalized treatment approaches could enhance care for individuals undergoing hormone therapy. This research underscores the adaptability of human biology and the need for healthcare providers to consider both shared and unique health risks in transgender women. To view or add a comment, sign in Recent research demonstrates that gender-affirming hormone therapy can significantly alter blood protein profiles in transgender women, aligning them more closely with those of cisgender women. To view or add a comment, sign in Here’s what research shows: 🔹 Key Study: A large 2016 study published in European Urology (by researchers from Harvard University) followed more than 30,000 men for almost two decades. They found that: • Men who ejaculated 21 or more times per month had about a 20% lower risk of developing prostate cancer than those who ejaculated 4–7 times per month. 🔹 What counts: Ejaculation frequency includes sex with a partner, masturbation, or nocturnal emissions. 🔹 Why it may help: More frequent ejaculation may help clear potentially harmful substances from the prostate and reduce inflammation, though the exact biological reason is still being studied. 🔹 Important context: • It’s not a prescription — just a correlation, not proof of cause and effect.

Sử dụng trong y tế

#MentalHealth #Entheogens #DepressionTreatment #Neuroplasticity #antidepressants #pharmaceuticals To view or add a comment, sign in 💊 Should patients really stop antidepressants before entheogen therapy? To view or add a comment, sign in Collaborence is the signature conference of the Psilocybin Assisted Therapy Association, a national nonprofit dedicated to advancing education, collaboration, and innovation in the world of psilocybin-assisted therapy. Designed for both professionals and the public, this event brings together leading voices in mental health, psychedelic research, and community advocacy to share evidence-based insights and diverse perspectives. Through panels, discussions, and networking, attendees are empowered to make informed decisions about the role of psilocybin in their personal and professional lives, while fostering connections that build stronger, more collaborative communities. Happening October 4-5, 2025, day one of The Collaborence offers online training and connection, and day two will feature two in-person expos: one in Portland, Oregon and one in Boulder, Colorado.

ATC (Anatomical Therapeutic Chemical Classification)

Be sure to check out Psychedelic Pharmacists Association members at: Day 1 October 4th Online 12:55pm – 1:40pm Psychedelics as Medicine: The Pharmacist’s Perspective Colby Burns, PharmD, MBA; April Huynh; Lauren Blue, PharmD, MS. ; Andy Krut; and Anne M Berg will explore the pharmacist’s role in evaluating and supporting psilocybin use for patients with complex comorbidities. Participants will walk away understanding: 💊 Key pharmacologic considerations, including psilocybin’s absorption, distribution, metabolism, excretion, and toxicity (ADMET), along with risks of combining psilocybin with other psychoactive or prescription substances. Special emphasis will be placed on drug–drug interaction screening, including the implications of tapering or discontinuing SSRIs. 🍄 What to expect during a psilocybin session, with attention to physiologic and psychological warning signs that warrant intervention. • Overall lifestyle (diet, exercise, weight, and not smoking) also strongly affects prostate health. • Men should still get regular prostate screenings as recommended by their doctor. ✅ Summary: Research suggests that around 21 ejaculations per month (roughly 4–5 times per week) is associated with the lowest risk of prostate cancer in men, compared with lower frequencies.

Product	Dosage	Quantity + Bonus	Price
Priligy Generic Dapoxetine	60mg	120 + 10 Pills	341.26€ 325.01€	Buy
Kamagra	100mg	120 + 6 Pills	330.74€ 314.99€	Buy
Priligy Generic Dapoxetine	60mg	20 + 4 Pills	77.31€ 73.63€	Buy
Apcalis SX Oral Jelly	20mg	70 + 7 Sachets	184.98€ 176.17€	Buy
Priligy Generic Dapoxetine	60mg	30 + 6 Pills	106.65€ 101.57€	Buy
Kamagra Gold	100 mg	12 Pills	55.64€ 52.99€	Buy
Priligy Generic Dapoxetine	60mg	180 + 10 Pills	494.76€ 471.20€	Buy
Priligy Generic Dapoxetine	60mg	10 Pills	47.63€ 45.36€	Buy
Viagra Professional	100mg	120 + 4 Pills	262.83€ 250.31€	Buy
Priligy Generic Dapoxetine	60mg	90 + 10 Pills	265.64€ 252.99€	Buy
Cialis Black	80mg	10 Pills	43.27€ 41.21€	Buy
Priligy Generic Dapoxetine	60mg	60 + 8 Pills	183.06€ 174.34€	Buy
Viagra Super Active	100mg	120 + 16 Pills	198.37€ 188.92€	Buy
Levitra Generic	60mg	360 + 10 Pills	906.69€ 863.51€	Buy
Viagra Original	100mg	8 Pills	59.84€ 56.99€	Buy

To view or add a comment, sign in 𝐆𝐋𝐏-1 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐀𝐥𝐜𝐨𝐡𝐨𝐥 𝐚𝐧𝐝 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 𝐔𝐬𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: 𝐀𝐧 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐫𝐢𝐦𝐞𝐫 Very interesting review just published in The Journal of the Endocrine Society by Nirupam Srinivasan and colleagues. ✍Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences.

Who should avoid Priligy?

🤓 Preclinical studies have consistently demonstrated the potential of GLP-1RAs in reducing the consumption and rewarding properties of alcohol, opioids, nicotine, and psychostimulants. 🤓Clinical studies remain limited for most substances but early results show reductions in cravings, substance use, and other related outcomes. Definitely worth reading!👍👏😀 To view or add a comment, sign in 𝐆𝐋𝐏-1 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐀𝐥𝐜𝐨𝐡𝐨𝐥 𝐚𝐧𝐝 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 𝐔𝐬𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: 𝐀𝐧 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐫𝐢𝐦𝐞𝐫 Very interesting review just published in The Journal of the Endocrine Society by Nirupam Srinivasan and colleagues. To view or add a comment, sign in ICD-10-CM Diagnosis Code Updates Total changes: 252 new codes, 36 deletions, 13 revisions Notable additions by chapter: Chapter 2 (Neoplasms): New codes for Hodgkin lymphoma in remission (e.g., C81.0A–C81.9A) Chapter 4 (Endocrine): Presymptomatic Type 1 diabetes (E10.A-), new obesity classifications (E66.811–E66.813), and MC4R pathway-related obesity (E88.82) Chapter 5 (Mental Disorders): Expanded eating disorder codes including anorexia nervosa subtypes, binge eating disorder, pica, and rumination disorder in adults Chapter 6 (Nervous System): New epilepsy codes (e.g., G40.84 for KCNQ2-related epilepsy), serotonin syndrome (G90.81), and developmental encephalopathy (G93.45) Chapter 9 (Circulatory System): Expanded pulmonary embolism codes (I26.03–I26.96) Chapter 10 (Respiratory System): New codes for nasal valve collapse under acute bronchiolitis (J21) 🛠️ ICD-10-PCS Procedure Code Updates These updates also take effect October 1, 2025, and apply to inpatient procedures through September 30, 2026. To view or add a comment, sign in 💊 Should patients really stop antidepressants before entheogen therapy?

Brand Names

A new 2025 review challenges one of the field’s most rigid assumptions. For decades, clinical trials with psilocybin, LSD, and DMT have required participants to discontinue antidepressants (SSRIs, SNRIs, MAOIs, etc.) weeks before an entheogen session. To “avoid serotonin syndrome” and “preserve the full psychedelic experience.” But the latest scoping review by Tap et al. (2025, Journal of Psychopharmacology) suggests this protocol may be both outdated and harmful. After analyzing 19 human studies across psilocybin, LSD, DMT, and ayahuasca, the authors found that: 🧠 Safety: There’s no robust evidence that taking antidepressants with classic entheogens increases the risk of serotonin toxicity — particularly with psilocybin. ✍However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. ✍Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs. ✍Following an overview of the epidemiology, biology, consequences, and treatments of ASUDs, this review provides a summary of the emerging role of GLP-1RAs in the treatment of ASUDs by elucidating their interactions with various neurobiological pathways involved in addiction.

Medication	Typical Dosage	Administration Time	Frequency
Dapoxetin	30 mg per dose	1-3 hours before sexual activity	Once daily or as needed
Sildenafil	50 mg, 100 mg, or 25 mg	30-60 minutes before activity	As needed, up to once daily
Tadalafil	10 mg, 20 mg, or 2.5 mg	30 minutes before activity	Once daily or as needed
Vardenafil	10 mg	25-60 minutes before activity	As needed
Dapoxetin	30 mg as a starting dose	1-3 hours before sexual activity	As needed

✍It also highlights existing gaps in research, future directions, and broader implications related to the potential use of GLP-1RAs for addiction treatment.

• There is no evidence that this combination affects fertility or sperm quality.
• Dapoxetine, as an SSRI, has been associated with slight changes in semen parameters.
• These changes are not thought to be clinically significant for fertility.
• Sildenafil has no known negative impact on sperm count or motility.
• Men trying to conceive should discuss any medications with their doctor.
• The drugs are not known to cause birth defects if a partner is exposed to semen.
• However, this is not a well-studied area, and caution is always advised.
• The primary focus of treatment is on the male partner's sexual function.
• The female partner's satisfaction is an important secondary outcome measure.
• Open communication between partners about the treatment is encouraged.
• Sexual dysfunction is a couples' issue, and treatment should involve both partners when possible.

🤓 Very interesting topic and well written paper 🤓Most of the times we talk about alcohol addiction and GLP-1RAs, however the topic si much broader.

Der Pharmacia Lettre

🥼 Pharmacist’s unique role across the continuum of care: ensuring safe screening, optimizing medication management, mitigating risks, and serving as a collaborative resource for patients and care teams engaging with psilocybin therapy. Day 2 October 5th Boulder, CO 🔹 10:30am – 4:30pm Kristin Speer, PharmD, BCPS and Erika Beerbower will be in the exhibition hall 🔸 1:30pm - 2:15pm Beyond Psychotropics: Relevant Psilocybin Interactions You Don't Want to Miss Dr. Kristin Speer, PharmD, BCPS, Kristin Speer, PharmD, BCPS will be discussing how psilocybin drug interaction info often focuses narrowly on psychotropics such as antidepressants, antipsychotics, and lithium. 🤓 Preclinical studies have consistently demonstrated the potential of GLP-1RAs in reducing the consumption and rewarding properties of alcohol, opioids, nicotine, and psychostimulants. 🤓Clinical studies remain limited for most substances but early results show reductions in cravings, substance use, and other related outcomes. Definitely worth reading!👍👏😀 To view or add a comment, sign in 𝐆𝐋𝐏-1 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐀𝐥𝐜𝐨𝐡𝐨𝐥 𝐚𝐧𝐝 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 𝐔𝐬𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: 𝐀𝐧 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐫𝐢𝐦𝐞𝐫 Very interesting review just published in The Journal of the Endocrine Society by Nirupam Srinivasan and colleagues. To view or add a comment, sign in ICD-10-CM Diagnosis Code Updates Total changes: 252 new codes, 36 deletions, 13 revisions Notable additions by chapter: Chapter 2 (Neoplasms): New codes for Hodgkin lymphoma in remission (e.g., C81.0A–C81.9A) Chapter 4 (Endocrine): Presymptomatic Type 1 diabetes (E10.A-), new obesity classifications (E66.811–E66.813), and MC4R pathway-related obesity (E88.82) Chapter 5 (Mental Disorders): Expanded eating disorder codes including anorexia nervosa subtypes, binge eating disorder, pica, and rumination disorder in adults Chapter 6 (Nervous System): New epilepsy codes (e.g., G40.84 for KCNQ2-related epilepsy), serotonin syndrome (G90.81), and developmental encephalopathy (G93.45) Chapter 9 (Circulatory System): Expanded pulmonary embolism codes (I26.03–I26.96) Chapter 10 (Respiratory System): New codes for nasal valve collapse under acute bronchiolitis (J21) 🛠️ ICD-10-PCS Procedure Code Updates These updates also take effect October 1, 2025, and apply to inpatient procedures through September 30, 2026.

Condition	Dapoxetin	Sildenafil
Cardiovascular disease	Use cautiously	Contraindicated with nitrates
Use with MAO inhibitors	Avoid	Avoid
Liver impairment	Dose adjustment required	Use with caution
Eye Disorders (e.g., retinitis pigmentosa)	No specific caution	Caution due to rare visual disturbances
Medication interactions	Serotonergic drugs may increase risk of serotonin syndrome	Other vasodilators or antihypertensives

To view or add a comment, sign in 💊 Should patients really stop antidepressants before entheogen therapy? A new 2025 review challenges one of the field’s most rigid assumptions. For decades, clinical trials with psilocybin, LSD, and DMT have required participants to discontinue antidepressants (SSRIs, SNRIs, MAOIs, etc.) weeks before an entheogen session. To “avoid serotonin syndrome” and “preserve the full psychedelic experience.” But the latest scoping review by Tap et al. (2025, Journal of Psychopharmacology) suggests this protocol may be both outdated and harmful. After analyzing 19 human studies across psilocybin, LSD, DMT, and ayahuasca, the authors found that: 🧠 Safety: There’s no robust evidence that taking antidepressants with classic entheogens increases the risk of serotonin toxicity — particularly with psilocybin. Most side effects (headache, mild nausea, temporary increases in blood pressure) were comparable to placebo.

Drug Name	Class	Mechanism of Action	Common Uses
Dapoxetin	Selective Serotonin Reuptake Inhibitor (SSRI)	Increases serotonin levels in the brain	Premature ejaculation treatment
Sildenafil	Phosphodiesterase type 5 (PDE5) inhibitor	Enhances blood flow by relaxing smooth muscles	Erectile dysfunction
Tadalafil	PDE5 inhibitor	Longer duration of action compared to sildenafil	Erectile dysfunction, BPH
Dapoxetin	SSRI - Short-acting	Rapid onset for premature ejaculation	Premature ejaculation
Vardenafil	PDE5 inhibitor	Similar to sildenafil, rapid onset	Erectile dysfunction
Sildenafil	PDE5 inhibitor	Vasodilation effect on penile blood vessels	Erectile dysfunction

💫 Efficacy: Even when antidepressants slightly blunted the intensity of the entheogenic experience, the therapeutic outcomes for depression and anxiety remained significant. In some studies, patients on antidepressants dapoxetine 30mg tablet improved as much or more than those who discontinued them. ⚠️ Risks of discontinuation: Forcing patients to stop antidepressants can lead to relapse, withdrawal symptoms, and suicidal ideation — all before entering a psychologically open and vulnerable state. In other words: the “washout” phase may do more harm than the drug combination itself. 🌱 The takeaway: Continuing antidepressants during entheogen-assisted therapy may actually increase accessibility and safety for millions who currently can’t participate in research or treatment.

Cơ chế hoạt động

Most side effects (headache, mild nausea, temporary increases in blood pressure) were comparable to placebo. 💫 Efficacy: Even when antidepressants slightly blunted the intensity of the entheogenic experience, the therapeutic outcomes for depression and anxiety remained significant. In some studies, patients on antidepressants dapoxetine 30mg tablet improved as much or more than those who discontinued them. ⚠️ Risks of discontinuation: Forcing patients to stop antidepressants can lead to relapse, withdrawal symptoms, and suicidal ideation — all before entering a psychologically open and vulnerable state. In other words: the “washout” phase may do more harm than the drug combination itself.

Global Distribution Network

🌱 The takeaway: Continuing antidepressants during entheogen-assisted therapy may actually increase accessibility and safety for millions who currently can’t participate in research or treatment. This isn’t just a pharmacological question — it’s an ethical one. If the future of mental health care is truly integrative, it must balance neurobiology with compassion, and clinical safety with real-world inclusion. Rigorous, trauma-informed trials that investigate how antidepressants modulate neuroplastic and subjective mechanisms of entheogenic therapy — without retraumatizing those who rely on them daily. Because healing shouldn’t require withdrawal to begin. This isn’t just a pharmacological question — it’s an ethical one. If the future of mental health care is truly integrative, it must balance neurobiology with compassion, and clinical safety with real-world inclusion. Rigorous, trauma-informed trials that investigate how antidepressants modulate neuroplastic and subjective mechanisms of entheogenic therapy — without retraumatizing those who rely on them daily.

• Store dapoxetin and sildenafil in a cool, dry place away from children.
• Do not share these medications with others.
• Always follow the prescribing guidelines and consult your doctor before use.

Because healing shouldn’t require withdrawal to begin. #MentalHealth #Entheogens #DepressionTreatment #Neuroplasticity #antidepressants #pharmaceuticals To view or add a comment, sign in 💊 Should patients really stop antidepressants before entheogen therapy?

Want to develop a new product?

The Journal of Biological Chemistry, 286(9), 6825–6838.) To view or add a comment, sign in Recent research demonstrates that gender-affirming hormone therapy can significantly alter blood protein profiles in transgender women, aligning them more closely with those of cisgender women. These changes may influence susceptibility to certain health conditions, including autoimmune diseases and heart disease. The findings highlight the importance of nuanced, long-term health monitoring and suggest that personalized treatment approaches could enhance care for individuals undergoing hormone therapy. This research underscores the adaptability of human biology and the need for healthcare providers to consider both shared and unique health risks in transgender women. To view or add a comment, sign in Recent research demonstrates that gender-affirming hormone therapy can significantly alter blood protein profiles in transgender women, aligning them more closely with those of cisgender women.

Xuất tinh sớm

To view or add a comment, sign in Here’s what research shows: 🔹 Key Study: A large 2016 study published in European Urology (by researchers from Harvard University) followed more than 30,000 men for almost two decades. They found that: • Men who ejaculated 21 or more times per month had about a 20% lower risk of developing prostate cancer than those who ejaculated 4–7 times per month. 🔹 What counts: Ejaculation frequency includes sex with a partner, masturbation, or nocturnal emissions. 🔹 Why it may help: More frequent ejaculation may help clear potentially harmful substances from the prostate and reduce inflammation, though the exact biological reason is still being studied. 🔹 Important context: • It’s not a prescription — just a correlation, not proof of cause and effect. To view or add a comment, sign in Collaborence is the signature conference of the Psilocybin Assisted Therapy Association, a national nonprofit dedicated to advancing education, collaboration, and innovation in the world of psilocybin-assisted therapy.

Possible Side Effects

• Overall lifestyle (diet, exercise, weight, and not smoking) also strongly affects prostate health. • Men should still get regular prostate screenings as recommended by their doctor. ✅ Summary: Research suggests that around 21 ejaculations per month (roughly 4–5 times per week) is associated with the lowest risk of prostate cancer in men, compared with lower frequencies. To view or add a comment, sign in 𝐆𝐋𝐏-1 𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜𝐬 𝐚𝐧𝐝 𝐓𝐡𝐞𝐢𝐫 𝐄𝐦𝐞𝐫𝐠𝐢𝐧𝐠 𝐑𝐨𝐥𝐞 𝐢𝐧 𝐀𝐥𝐜𝐨𝐡𝐨𝐥 𝐚𝐧𝐝 𝐒𝐮𝐛𝐬𝐭𝐚𝐧𝐜𝐞 𝐔𝐬𝐞 𝐃𝐢𝐬𝐨𝐫𝐝𝐞𝐫𝐬: 𝐀𝐧 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 𝐏𝐫𝐢𝐦𝐞𝐫 Very interesting review just published in The Journal of the Endocrine Society by Nirupam Srinivasan and colleagues. ✍Alcohol and other substance use disorders (ASUDs) are complex, multifaceted, but treatable medical conditions with widespread medical, psychological, and societal consequences.

CAS registry number (Chemical Abstracts Service)

✍However, treatment options remain limited, therefore the discovery and development of new treatments for ASUDs is critical. ✍Glucagon-like peptide-1 receptor agonists (GLP-1RAs), currently approved for the treatment of type 2 diabetes mellitus, obesity, and obstructive sleep apnea, have recently emerged as potential new pharmacotherapies for ASUDs. ✍Following an overview of the epidemiology, biology, consequences, and treatments of ASUDs, this review provides a summary of the emerging role of GLP-1RAs in the treatment of ASUDs by elucidating their interactions with various neurobiological pathways involved in addiction. ✍It also highlights existing gaps in research, future directions, and broader implications related to the potential use of GLP-1RAs for addiction treatment. 🤓 Very interesting topic and well written paper 🤓Most of the times we talk about alcohol addiction and GLP-1RAs, however the topic si much broader. Designed for both professionals and the public, this event brings together leading voices in mental health, psychedelic research, and community advocacy to share evidence-based insights and diverse perspectives. Through panels, discussions, and networking, attendees are empowered to make informed decisions about the role of psilocybin in their personal and professional lives, while fostering connections that build stronger, more collaborative communities. Happening October 4-5, 2025, day one of The Collaborence offers online training and connection, and day two will feature two in-person expos: one in Portland, Oregon and one in Boulder, Colorado. Be sure to check out Psychedelic Pharmacists Association members at: Day 1 October 4th Online 12:55pm – 1:40pm Psychedelics as Medicine: The Pharmacist’s Perspective Colby Burns, PharmD, MBA; April Huynh; Lauren Blue, PharmD, MS. ; Andy Krut; and Anne M Berg will explore the pharmacist’s role in evaluating and supporting psilocybin use for patients with complex comorbidities. Participants will walk away understanding: 💊 Key pharmacologic considerations, including psilocybin’s absorption, distribution, metabolism, excretion, and toxicity (ADMET), along with risks of combining psilocybin with other psychoactive or prescription substances. Special emphasis will be placed on drug–drug interaction screening, including the implications of tapering or discontinuing SSRIs. 🍄 What to expect during a psilocybin session, with attention to physiologic and psychological warning signs that warrant intervention.

• The economic burden of untreated sexual dysfunction can be significant.
• It can lead to relationship breakdown, anxiety, and depression.
• Effective treatment can improve overall mental health and well-being.
• The cost of medication must be weighed against these potential benefits.
• Patient assistance programs may be available for those who cannot afford treatment.
• The global market for ED and PE medications is vast and highly profitable.
• This commercial interest drives both innovation and questionable marketing practices.
• Patients should rely on information from unbiased medical sources.
• Websites of national health services or medical associations are reliable.
• Forums and social media can spread misinformation and should be used cautiously.
• The decision to treat should be based on medical need, not commercial pressure.

🥼 Pharmacist’s unique role across the continuum of care: ensuring safe screening, optimizing medication management, mitigating risks, and serving as a collaborative resource for patients and care teams engaging with psilocybin therapy.

What does Priligy do to your body?

Day 2 October 5th Boulder, CO 🔹 10:30am – 4:30pm Kristin Speer, PharmD, BCPS and Erika Beerbower will be in the exhibition hall 🔸 1:30pm - 2:15pm Beyond Psychotropics: Relevant Psilocybin Interactions You Don't Want to Miss Dr. Kristin Speer, PharmD, BCPS, Kristin Speer, PharmD, BCPS will be discussing how psilocybin drug interaction info often focuses narrowly on psychotropics such as antidepressants, antipsychotics, and lithium.

• The demographic most commonly prescribed this combination is middle-aged men.
• However, it can be considered for adult men of any age after proper diagnosis.
• Efficacy and safety in elderly patients (>65) have not been extensively studied.
• Dosing for older patients usually starts at the lowest possible amounts.
• Age-related decline in liver and kidney function affects drug metabolism.
• Comorbid conditions are more common in older adults, increasing interaction risks.
• The combination is not studied or used in men with spinal cord injuries.
• It is also not indicated for men with anatomical deformities of the penis.
• Penile implants or other surgical interventions are alternative options.
• The field of sexual medicine is evolving, with new treatments constantly emerging.
• This combination represents a pragmatic approach to a complex clinical problem.